TFF Announces Data from Phase 1 Study of Niclosamide

Niclosamide Inhalation Powder Well Tolerated with No Serious Adverse Events Across All Subject Cohorts Current Data Suggests Niclosamide Inhalation Powder is a Promising Antiviral Treatment to Combat COVID-19

Daniel Carlson

April 19, 2022

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

3 COMMENTS

randy123 April 20, 2022 at 12:16 pm

You need to login to view this content.

Reply
thinfilmfreezer April 19, 2022 at 5:07 pm

You need to login to view this content.

Reply
pfalker April 19, 2022 at 10:06 am

You need to login to view this content.

Reply

LEAVE A REPLY Cancel reply

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.